The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and health systems.
PARADIGM SHIFTS, ESPECIALLY IN MEDICINE, DO NOT HAPPEN JUST BECAUSE THE SCIENCE AND NEW TECHNOLOGIES SUGGEST THEY SHOULD.

Based on this assumption, some 20 institutions launched the Personalized Medicine Coalition in 2004 to develop a new medical paradigm that links treatment decisions to diagnostics.

Believing in an ecosystem of shared value across the multiple stakeholders it represents, the Coalition advocates for changes that will increase investment in personalized medicine and facilitate its clinical adoption so that both patients and health systems will benefit from improved health care and increased efficiency.

WHAT IS PERSONALIZED MEDICINE?

Personalized medicine is an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each patient or use medical interventions to alter molecular mechanisms that impact health. By combining data from diagnostic tests with an individual’s medical history, circumstances and values, health care providers can develop targeted treatment and prevention plans with their patients.
PMC WORKS TO ENSURE THAT POLICIES AND PRACTICES IN THE PUBLIC AND PRIVATE SECTORS PAVE THE WAY FOR PERSONALIZED MEDICINE.

Based in Washington, D.C., PMC works closely with health systems, lawmakers and agency officials to advance strategic priorities in three areas:

• **Education:** To raise the profile and scope of personalized medicine, PMC proactively educates decision-makers and patients about how the field can make health systems more effective and efficient by targeting better treatments to only those who will benefit.

• **Advocacy:** To help facilitate the development of personalized medicine tests and therapies, PMC engages policymakers to advocate for continued investments in biomedical research as well as modernized regulatory, coverage and payment policies that support access to personalized medicine.

• **Evidence Development:** To encourage the swifter adoption of personalized medicine by payers and health care providers, PMC helps build the evidence base necessary to demonstrate the clinical and economic value of personalized medicine.

“Personalized medicine is transforming the practice of medicine, and PMC is playing a critical role in bringing together all of the stakeholders to help make that happen.”

— Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School
PMC MEMBERS ARE LEADING THE MOVEMENT TOWARD PERSONALIZED MEDICINE TO BENEFIT PATIENTS AND HEALTH SYSTEMS AROUND THE WORLD.

MEMBER COMMITTEES/WORKING GROUPS

- **Public Policy Committee**
  - Patient Advocacy Organization Working Group
  - Pharmaceutical and Diagnostics Working Group

- **Science Policy Committee**
  - Health Care Working Group
  - Value Assessment Working Group

- **Additional Working Groups**
  - Health Data Working Group
  - Pharmacogenomics Working Group

MEMBER BENEFITS

<table>
<thead>
<tr>
<th>Contact</th>
<th>Interact with</th>
<th>Save</th>
</tr>
</thead>
<tbody>
<tr>
<td>2,000+ leaders in personalized medicine via PMC’s member database</td>
<td>200+ thought leaders from Congress, FDA, CMS and the private sector at member meetings and events</td>
<td>40% on registration for the Annual Personalized Medicine Conference</td>
</tr>
</tbody>
</table>

Attend Member Meetings and Events at no charge

Receive Copies of PMC publications and reports
PMC MEMBERSHIP

PMC is an international, multi-stakeholder 501(c)3 nonprofit organization with members that are committed to science-driven, evidence-based health care.

CLINICAL LABORATORY TESTING SERVICES
Blue Genes
Invitae
Laboratory Corporation of America (Labcorp)
Quest Diagnostics
SmartLabs

DIAGNOSTIC COMPANIES
10x Genomics
Agenda NV
Agilent Technologies
Biological Dynamics
Castle Biosciences
Circulogene
Cofactor Genomics
Delfi Diagnostics
Exact Sciences
Exai Bio
Foundation Medicine, Inc.
GeneCentric Therapeutics
GRAIL, Inc.
Guardant Health
Illumina
Myriad Genetics
NanoString Technologies
NeoGenomics Laboratories
Olaris, Inc.
Oncoocyte
Quibim
Roche Diagnostics
Singular Genomics
SomaLogic, Inc.
Thermo Fisher Scientific

EMERGING BIOTECH/PHARMACEUTICAL COMPANIES
1cBio
Actio Biosciences
Adaptive Biotechnologies
Alexion Pharmaceuticals
Day One Bio
Denovo Biopharma
Elevation Oncology, Inc.
Freenome
Helix
ImmunoGen
Jazz Pharmaceuticals
Kyverna Therapeutics
Merus
OneOme
Rapafusyn
Pharmaceuticals

HEALTH INSURANCE COMPANIES
Point32Health

INDUSTRY/TRADE ASSOCIATIONS
American Clinical Laboratory Association
Biocom California
National Society of Genetic Counselors
PhRMA

IT/INFORMATICS COMPANIES
Aetion
Aitia
Aranscia
Assurance Health Data
Aster Insights
BC Platforms
Change Healthcare
Concert Genetics
DNAnexus
Flatiron Health
Nucleai
Oxford Nanopore Technologies
PathAI
Syapse
Translational Software
Verily Life Sciences

LARGE BIOTECH/PHARMACEUTICAL COMPANIES
AbbVie
Amgen, Inc.
Astellas
AstraZeneca Pharmaceuticals
Bausch Health Companies
Biogen
Blueprint Medicines
Bristol Myers Squibb
Eli Lilly and Company
Genentech, Inc.
Gilead
GlaxoSmithKline
Johnson & Johnson
Merck & Co.
Novartis
Pfizer, Inc.
Sanofi

PATIENT ADVOCACY GROUPS
Accelerated Cure Project for Multiple Sclerosis
AiArthritis
Alliance for Aging Research
Alzheimer’s Foundation of America
American Association of Kidney Patients (AAKP)
American Cancer Society Cancer Action Network (ACS-CAN)
Bulgarian Association for Personalized Medicine
Cancer Treatment Options & Management Inc. (CTOAM)
Colorectal Cancer Alliance
Emily’s Entourage
EveryLife Foundation for Rare Disease
Friends of Cancer Research
Glioblastoma Foundation
Global Liver Institute
GO2 for Lung Cancer International
International Cancer Advocacy Network
As of January 2024

KIAS Kickers
LUNGevity Foundation
Multiple Myeloma Research Foundation
National Alliance Against Disparities in Patient Health
National Alliance for Hispanic Health
National Health Council
National Pancreas Foundation
Rabble Health
Sepsis Alliance
Support Fibromyalgia Network
SynGAP Research Fund
TargetCancer Foundation
Team Trevor
The Assistance Fund

PERSONALIZED MEDICINE SERVICE PROVIDERS
CareDx
Coriell Life Sciences
InformedDNA
Michael J. Bauer, M.D., & Associates, Inc.
My Gene Counsel
QURE Healthcare
Tempus

RESEARCH, EDUCATION & CLINICAL CARE INSTITUTIONS
AccelevarDx
AdventHealth
American Association for Cancer Research (AACR)
American Medical Association (AMA)
American Society of Health System Pharmacists (ASHP)
Arizona State University
Association for Molecular Pathology (AMP)
Audubon Bioscience
Business Finland
Cancer Treatment Centers of America
Cedars-Sinai
Clarified Precision Medicine
Codex4SMEs
Colorado Center for Personalized Medicine
CommonSpirit Health
Coriell Institute for Medical Research
Culmination Bio
Duke Center for Research
Essentia Institute of Rural Health
European Infrastructure for Translational Medicine (EATRIS)
Genome Canada
Hamad Medical Corporation
Hospital Albert Einstein
ICAN – Digital Precision Cancer Medicine at University of Helsinki
Intermountain Healthcare
King Faisal Specialist Hospital and Research Centre
MaineHealth Accountable Care Organization
Manchester University School of Pharmacy
Marshfield Clinic
Mayo Clinic
MD Anderson – Institute for Personalized Cancer Therapy
Moffitt Cancer Center
Morehouse School of Medicine
National Pharmaceutical Council
Nicklaus Children’s Hospital Research Institute
North Carolina Biotechnology Center (NCBIO)
NorthShore University Parkview Health
Qatar Biobank
Sanford Imagenetics, Sanford Health
Teachers’ Retirement System of Kentucky
The Christ Hospital
The Jackson Laboratory
Translational Genomics Research Institute (Tgen)
UC Davis Mouse Biology Program
University of Alabama, Birmingham
University of California, San Francisco (UCSF)
University of Chicago
University of Pennsylvania Health System
University of Pittsburgh Medical Center (UPMC)
University of South Florida
Morsani College of Medicine

RESEARCH TOOL COMPANIES
Octave Biosciences

STRATEGIC PARTNERS
ADVI
Arnold & Porter
Avalere
Bradford Power
Bruce Quinn Associates
Cambridge Healthtech Institute
Carol Colman
Catalytic Agency
Clinical Transformation Partners
ConText
ConvergeHEALTH by Deloitte
Deverka Consulting
Diacetus
Foley & Lardner, LLP
Foley Hoag, LLP
Genome Creative
Goldbug Strategies, LLC
Harbor Precision Genomics
Health Advances, LLC
Innovation Horizons
Innovation Policy Solutions
KPMG
L.E.K. Consulting
McDermott Will & Emery
DUES STRUCTURE
As of January 2024

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Large Public Corporation</td>
<td>$38,000</td>
</tr>
<tr>
<td>Small Public Corporation</td>
<td>$19,000</td>
</tr>
<tr>
<td>Trade Association (based on revenues)</td>
<td></td>
</tr>
<tr>
<td>Private Corporation &gt;15 FTEs</td>
<td>$7,150</td>
</tr>
<tr>
<td>Private Corporation &lt;15 FTEs</td>
<td>$3,500</td>
</tr>
<tr>
<td>Strategic Partner &gt;5 FTEs</td>
<td>$3,700</td>
</tr>
<tr>
<td>Strategic Partner &lt;5 FTEs</td>
<td>$1,700</td>
</tr>
<tr>
<td>Research, Education &amp; Clinical Care Institutions</td>
<td>$3,500</td>
</tr>
<tr>
<td>Patient Advocacy Group</td>
<td>$500</td>
</tr>
</tbody>
</table>

Visit members.personalizedmedicinecoalition.org to join the Coalition.

For more information, contact Kayla Brown, Vice President, Membership & Development, at kbrown@personalizedmedicinecoalition.org.
STAFF

Edward Abrahams, Ph.D.
President

Faswilla Sampson, M.S.
Chief Operating Officer

Cynthia A. Bens
Senior Vice President,
Public Policy

Daryl Pritchard, Ph.D.
Senior Vice President,
Science Policy

Christopher J. Wells, M.P.A.
Senior Vice President, Public Affairs

Kayla Brown
Vice President, Membership &
Development

David L. Davenport
Manager, Public and Science Policy

Lindsay Stephens
Director, Operations & Secretary
to the Board

BOARD OF DIRECTORS

Lincoln Nadauld, M.D., Ph.D.
Chair
CEO, Culmination Bio

Lauren Silvis, J.D.
Vice Chair
Tempus

Peter Maag, Ph.D.
Treasurer
Kyverna Therapeutics

Michael Sherman, M.D.
Secretary
RA Capital Management

Gabriele Allegri
Johnson & Johnson Innovative Medicine

Antonio L. Andreu, M.D., Ph.D.
European Infrastructure for Translational Medicine (EATRIS)

Randy Burkholder
PhRMA

Dawn Cardeiro
Point32Health

Brian Caveney, M.D.
Labcorp

William S. Dalton, Ph.D., M.D.
Aster Insights

Stephen L. Eck, M.D., Ph.D.
MacroGenics

Helmy Eltoukh, Ph.D.
Guardant Health

Lori Frank, Ph.D.
The New York Academy of Medicine

Sarah Hersey
Bristol Myers Squibb

Steffan Ho, M.D., Ph.D.
Pfizer

Richard Knight
American Association of Kidney Patients

Mia Levy, M.D., Ph.D.
Foundation Medicine

James W. Lillard, Ph.D.
Morehouse School of Medicine

Howard McLeod, Pharm.D.
Clariﬁed Precision Medicine

J. Brian Munroe
Bausch Health Companies Inc.

Elizabeth O’Day, Ph.D.
Olaris, Inc.

Joshua Ofman, M.D.
Grail

Prasanth Reddy, M.D.
Apostolia-Maria Tsimberidou,
M.D., Ph.D.
The University of Texas MD Anderson Cancer Center

Michael J. Vasconcelles, M.D.
ImmunoGen

Jay G. Wohlgemuth, M.D.
Trusted Health Advisors

PERSONALIZED MEDICINE COALITION
1710 Rhode Island Ave., NW, Suite 700
Washington, DC 20036
pmc@personalizedmedicinecoalition.org